Re-Mission is a third-person shooter video game released by the non-profit organization HopeLab on April 3, 2006.
The game falls primarily within the serious games genre, is intended to be both informative and entertaining, and is designed for young persons with cancer. The game was the culmination of years of research to ensure that it addressed realistic cancer-related medical issues within the context of entertaining gameplay.
An epic battle rages deep in the realms of the human body. Colonies of microscopic cancer cells replicate, attack and damage healthy orgrans. Enter Roxxi, a gutsy and fully armed nanobot, and medicine’s mightiest warrior. Lead here through challenging missions and rapid-fire assaults on malignant cells, wherever they hide. It’s the world’s smallest battlefield, yet the stakes have never been higher.
In Re-Mission, the player controls an RX5-E (“Roxxi”) nanobot who is designed to be injected into the human body and fight particular types of cancer and related infections at a cellular level. The player must also monitor patient health and report any symptoms back to Dr. West (the in-game doctor and project leader). Each of the 20 levels is designed to inform the patient on a variety of treatments, how they function, and the importance of maintaining strict adherence to those treatments.
Fighting cancer is an inside job. Guide Roxxi through the complex environments of the human body. Wreak havoc on cancer. Fire weapons like the chemo blaster, the radiotion gun and the anti-biotic rocket. Combat malignancies like non-hidgkin’s lumphoma and leukemia. Combine gameplay with science. Every re-mission adventure fuses action and accuracy.
I hope this game can be used by our hospitals to help cancer patients understand what the disease is all about and at the same time patients gaining more confidence in winning the battle by playing the game.
Re-Mission is available at no charge to young people with cancer and health care providers by visiting the game’s official website at http://www.re-mission.net/
